LAM561の新興薬剤に関する洞察と市場予測：2032年

LAM561（2-OHOA：2-ヒドロキシオレイン酸）は、細胞膜脂質の修飾を介して作用するファースト・イン・クラスの抗がん剤です。LP561A1は、経口で生物学的に利用可能なオレイン酸の合成誘導体であり、血液脳関門を通過してSMS1の発現を活性化し、Rasシグナル調節作用を示します。この重要な酵素は、細胞膜のリン脂質濃度、特にスフィンゴ脂質の濃度を調節します。がん細胞では、膜脂質の組成と構造が著しく変化しています。これらの変化は、K-Rasのような中心的な増殖シグナル伝達タンパク質の細胞膜への動員を増加させることが観察されています。Ras関連増殖シグナル伝達経路の異常な活性は、ヒトがんの少なくとも3分の1に見られます。この薬剤は、K-Rasの細胞膜における活性ドメインから細胞質膜への転位を誘導し、そのナノクラスター化とシグナル伝達を阻害することで、主要なRas依存性増殖経路（Ras/MAPK、Pi3K/ACT/mTOR、PKC/サイクリンCDKなど）を不活性化し、小胞体ストレス、細胞周期の停止、そして最終的にはがん細胞の選択的死滅を引き起こします。

今後数年間で、多形性膠芽腫（GBM）の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、LAM561の優位性に影響を与える可能性のある機会を模索しています。GBMに対する他の新興製品がLAM561に厳しい市場競争を与えることが予想され、近い将来、後発の新興治療薬の発売が市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるLAM561市場について調査し、市場の概要とともに、2024年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 多形性膠芽腫（GBM）に対するLAM561の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 LAM561市場評価

• GBMに対するLAM561の市場見通し
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるGBMに対するLAM561の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: LAM561, Clinical Trial Description, 2023
• Table 2: LAM561, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: LAM561 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: LAM561 Market Size in the US, in USD million (2019-2032)
• Table 7: LAM561 Market Size in Germany, in USD million (2019-2032)
• Table 8: LAM561 Market Size in France, in USD million (2019-2032)
• Table 9: LAM561 Market Size in Italy, in USD million (2019-2032)
• Table 10: LAM561 Market Size in Spain, in USD million (2019-2032)
• Table 11: LAM561 Market Size in the UK, in USD million (2019-2032)
• Table 12: LAM561 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: LAM561 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: LAM561 Market Size in the United States, USD million (2019-2032)
• Figure 3: LAM561 Market Size in Germany, USD million (2019-2032)
• Figure 4: LAM561 Market Size in France, USD million (2019-2032)
• Figure 5: LAM561 Market Size in Italy, USD million (2019-2032)
• Figure 6: LAM561 Market Size in Spain, USD million (2019-2032)
• Figure 7: LAM561 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: LAM561 Market Size in Japan, USD million (2019-2032)

“"LAM561 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LAM561 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the LAM561 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the LAM561 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LAM561 market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

LAM561 (2-OHOA: 2-hydroxyoleic acid) is the first-in-class anticancer drug acting through cell membrane lipid modification. LP561A1 is an orally bioavailable synthetic derivative of oleic acid that crosses the blood-brain barrier and activates SMS1 expression with Ras signaling modulator effects. This key enzyme regulates phospholipid concentrations at the plasma membrane, particularly sphingolipid. Membrane lipid composition and organization are significantly altered in cancer cells. These changes have been observed to increase recruitment to the cell membrane of central proliferation signaling proteins, such as K-Ras. Aberrant activity of Ras-associated proliferative signaling pathways is found in at least one-third of all human cancers. It induces translocation of K-Ras from its active domain in the plasma membrane to the cytosolic membranes and inhibits its nanoclustering and signaling, inactivating key Ras-dependent proliferation pathways (like Ras/MAPK, Pi3K/AKT/mTOR or PKC/Cyclin CDK), causing endoplasmic reticulum stress, cell cycle arrest and eventually selective death of cancer cells.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the LAM561 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on LAM561 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the LAM561 research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around LAM561.
• The report contains forecasted sales of LAM561 for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for LAM561 in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LAM561 Analytical Perspective by DelveInsight

In-depth LAM561 Market Assessment

This report provides a detailed market assessment of LAM561 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

LAM561 Clinical Assessment

The report provides the clinical trials information of LAM561 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LAM561 dominance.
• Other emerging products for GBM are expected to give tough market competition to LAM561 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LAM561 in GBM.
• Our in-depth analysis of the forecasted sales data of LAM561 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LAM561 in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of LAM561?
• What is the clinical trial status of the study related to LAM561 in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LAM561 development?
• What are the key designations that have been granted to LAM561 for GBM?
• What is the forecasted market scenario of LAM561 for GBM?
• What are the forecasted sales of LAM561 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to LAM561 for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

Table of Contents

1. Report Introduction

2. LAM561 Overview in GBM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. LAM561 Market Assessment

• 5.1. Market Outlook of LAM561 in GBM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of LAM561 in the 7MM for GBM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of LAM561 in the United States for GBM
  • 5.3.2. Market Size of LAM561 in Germany for GBM
  • 5.3.3. Market Size of LAM561 in France for GBM
  • 5.3.4. Market Size of LAM561 in Italy for GBM
  • 5.3.5. Market Size of LAM561 in Spain for GBM
  • 5.3.6. Market Size of LAM561 in the United Kingdom for GBM
  • 5.3.7. Market Size of LAM561 in Japan for GBM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options